A Phase 4 interventional study of Alpha1-Proteinase Inhibitor in Alpha 1-Antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 15th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 4, and was the 5th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2006.
This study's enrollment of 21 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
14 studies in alpha 1-Antitrypsin Deficiency by Takeda: 3 open now, 4 under way, 3 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 4, and was the 5th registered.
Takeda’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Takeda’s 14 in alpha 1-Antitrypsin Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of weekly augmentation therapy with ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor levels and other ELF analytes and to assess the safety of the treatment. Eligible subjects with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8 consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered intravenously. The efficacy and safety assessments will include two bronchoscopies with bronchoalveolar lavage on study initiation and on study termination and multiple imaging and laboratory safety assessments. Each subject will participate for a minimum of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pulmonary functions at screening meeting the following criteria:
Laboratory results obtained at the screening visit, meeting the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/kg, weekly, intravenous infusion
Also known as: ARALAST Fr.IV-1, ARALAST NP
Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level
Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min
Time frame: During 8 consecutive weeks of treatment
Number of Changes in the Rate of Infusion
Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min
Time frame: During 8 consecutive weeks of treatment
Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels
Median ratio of post- to pre-treatment BAL ELF ANEC levels
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Change in in the Ratio of BAL ELF α1-PI to Human Neutrophil Elastase (HNE) Complex Concentration
Median change in the ratio of BAL ELF α1-PI to HNE complex concentration from baseline to post-treatment
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Change in the α1-PI Plasma Level
Mean change in the plasma level of α1-PI from baseline to post-treatment
Time frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level
Mean change in the plasma ANEC level from baseline to post-treatment
Time frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion
Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: ≥ 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to \>38°C (\>100.4°F). If the pre-infusion body temperature was already \>38°C (\>100.4°F), then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant. • Respiratory rate: 25% increase above pre-infusion value
Time frame: During 8 consecutive weeks of infusion
Change in the BAL ELF Free Neutrophil Elastase Level
Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level
Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level
Median ratio of post- to pre-treatment BAL ELF IL-8 Level
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Change in the BAL ELF Tumor Necrosis Factor-alpha (TNF-α) From Baseline to Post-treatment
Median change in the BAL ELF TNF-α from baseline to post-treatment
Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Participants were recruited at 5 hospital sites in New Zealand and Australia. The period studied was 1 year and 2 months.
| Milestone | Participants Treated With ARALAST Fraction IV-1 (Fr. IV-1) |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment
| μM | Per Protocol |
|---|---|
| Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level | 0.28 (-0.24 to 4.90) |
| adverse events | Intent to Treat |
|---|---|
| The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min | 0 |
Median ratio of post- to pre-treatment BAL ELF ANEC levels
| μM | Per Protocol |
|---|---|
| Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels | 1.22 (0.63 to 1.81) |
Median change in the ratio of BAL ELF α1-PI to HNE complex concentration from baseline to post-treatment
No measurements were reported for this outcome.
Mean change in the plasma level of α1-PI from baseline to post-treatment
| μM | Per Protocol |
|---|---|
| Change in the α1-PI Plasma Level | 10.34 ± 2.50 |
Mean change in the plasma ANEC level from baseline to post-treatment
| μM | Per Protocol |
|---|---|
| Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level | 9.46 ± 2.31 |
Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment
| nM | Per Protocol |
|---|---|
| Change in the BAL ELF Free Neutrophil Elastase Level | 41.17 (3.91 to 41.61) |
Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level
| nM | Per Protocol |
|---|---|
| Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level | 1.24 (0.47 to 30.97) |
Median ratio of post- to pre-treatment BAL ELF IL-8 Level
| pg/mL | Per Protocol |
|---|---|
| Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level | 1.46 (0.48 to 10.38) |
Median change in the BAL ELF TNF-α from baseline to post-treatment
No measurements were reported for this outcome.
Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min
| infusions | Intent to Treat |
|---|---|
| Number of Changes in the Rate of Infusion | 0 |
Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: ≥ 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to \>38°C (\>100.4°F). If the pre-infusion body temperature was already \>38°C (\>100.4°F), then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant. • Respiratory rate: 25% increase above pre-infusion value
| # Clinically significant events | Intent to Treat |
|---|---|
| Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion | 2 |
Collected over 1 year, 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intent to Treat | — | 1/13 (7.7%) | 7/13 (53.8%) |
| Event | Intent to Treat |
|---|---|
| Hepatitis A antibody positiveInvestigations | 1/13 |
| Event | Intent to Treat |
|---|---|
| SluggishnessGeneral disorders | 2/13 |
| Post procedural complicationInjury, poisoning and procedural complications | 2/13 |
| InflammationGeneral disorders | 1/13 |
| Vessel puncture site haematomaGeneral disorders | 1/13 |
| BronchitisInfections and infestations | 1/13 |
| SinusitisInfections and infestations | 1/13 |
| ContusionInjury, poisoning and procedural complications | 1/13 |
| Blood pressure systolic abnormalInvestigations | 1/13 |
| Respiratory rate increasedInvestigations | 1/13 |
| Back painMusculoskeletal and connective tissue disorders | 1/13 |
| Age, Categorical(Participants) | Participants Treated With ARALAST Fr. IV-1 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 3 |
| Age, Continuous(years) | Participants Treated With ARALAST Fr. IV-1 |
|---|---|
| Median | 59.6 (36.0 to 76.1) |
| Sex: Female, Male(Participants) | Participants Treated With ARALAST Fr. IV-1 |
|---|---|
| Female | 6 |
| Male | 7 |
| Region of Enrollment(Participants) | Participants Treated With ARALAST Fr. IV-1 |
|---|---|
| Australia | 8 |
| New Zealand | 5 |
Ran from Oct 2006 to primary completion in Dec 2007, 13 months.
Results were first posted in Jan 2011, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →